Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mureema Solberg

Family Medicine Newton, IA Medical Doctor

NPI 1609812064 CMS profile 864235

300 N 4Th Ave E, Suite 200, Newton, IA 50208

Open in the dashboard

General payments

$9,286

666 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mureema Solberg of Newton, IA is reported in the CMS Open Payments database as having received $9,286 across 666 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,184 59
2024 General $1,025 67
2023 General $1,148 73
2022 General $1,474 95
2021 General $1,746 136
2020 General $1,024 93
2019 General $1,685 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mureema Solberg
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Mureema Solberg were reported at $1,184. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Mureema Solberg Family Medicine median Middle half National median
2019 $1,685 $150 $41–$543 $163
2020 $1,024 $120 $32–$415 $114
2021 $1,746 $137 $35–$551 $132
2022 $1,474 $137 $37–$512 $149
2023 $1,148 $149 $42–$545 $160
2024 $1,025 $156 $44–$560 $164
2025 $1,184 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,067 93 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $850 56 payments
  3. Novo Nordisk Inc $701 51 payments
  4. AstraZeneca Pharmaceuticals LP $548 26 payments
  5. AbbVie, Inc. $543 41 payments
  6. Lilly USA, LLC $466 33 payments
  7. Sanofi-Aventis U.S. LLC $392 24 payments
  8. Amgen Inc. $379 27 payments
  9. GlaxoSmithKline, LLC. $365 27 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $353 22 payments
  11. Other $3,620 266 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,237 664 payments
  2. Education $49 2 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $484 45 payments
  2. XIFAXAN $446 28 payments
  3. COMIRNATY $394 28 payments
  4. RYBELSUS $393 32 payments
  5. Ozempic $391 34 payments
  6. SPIRIVA RESPIMAT $380 21 payments
  7. BREZTRI $362 15 payments
  8. XARELTO $348 30 payments
  9. JARDIANCE $334 27 payments
  10. PREVNAR 20 $301 17 payments
  11. Other $9,941 689 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

4,320

Median for Family Practice: 1,826

Drug cost

$422,923

Median for Family Practice: $120,094

Branded share of claims

19.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 86 $115,299
Eliquis Apixaban Brand 64 $49,858
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $39,697
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 29 $26,651
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 36 $25,874
Farxiga Dapagliflozin Propanediol Brand 14 $21,257
Linzess Linaclotide Brand 20 $18,667
Mounjaro Tirzepatide Brand 12 $14,705
Xarelto Rivaroxaban Brand 15 $14,298
Myrbetriq Mirabegron Brand 12 $11,025

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$67,520

Of which drugs: $16,680

Medicare patients

165

Average age 74

Services billed

1,794

145 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Chronic kidney disease 47%
Diabetes 26%
Osteoporosis 18%
Ischemic heart disease 17%
Depression 14%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 45 51 $7,454
Pcv20 vaccine im 90677 Office 20 20 $5,759
Vaccine for influenza for injection into muscle 90662 Office 45 46 $3,372

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $118
$118 — —
ZAVZPRET
  • PFIZER INC. $98
$98 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $65
  • Lilly USA, LLC $32
$97 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $71
$71 29 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

666 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record